Biotech Values

[DewDiligence]

Re: EXAS PoC data on lung-nodule test /AACR

EXAS’ most advanced pipeline program is to detect whether lung nodules are cancerous, based on a blood test; like Cologuard, this program is being developed using technology exclusively licensed from the Mayo Clinic:

http://finance.yahoo.com/news/exact-sciences-mayo-clinic-study-223100285.html

EXAS hasn’t yet committed to conducting a large RCT for the lung-nodule test (i.e. a phase-3 trial similar to the DEEP-C study that was the basis for FDA approval of Cologuard). However, if EXAS decides to seek commercialization of the lung-nodule test, they will not settle for a mere LDT, but rather will go all out for FDA approval to market the test (as with Cologuard).

Lung nodules are extremely common, so an accurate blood test to ascertain whether they are cancerous would have high medical value.